Advances in the management of inflammatory bowel disease.
Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically examines the evidence for these new developments and aims to provide an overview for medical professionals involved in the care of patients with IBD. Proposed changes in the use of aminosalicylates, immunosuppressants and biological agents are described, and the evidence for several promising novel agents is reviewed.
Grimpen
F
F
Department of Gastroenterology and Hepatology, St George Hospital, Kogarah, New South Wales, Australia. fgrimpen@hotmail.com
Pavli
P
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use; D001688:Biological Products / Q000493:pharmacokinetics / Q000627:therapeutic use; D019468:Disease Management; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*
D000911:Antibodies, Monoclonal; D001688:Biological Products; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents